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MetastasisHowmutations or dysfunction of CFTR may increase the risk of malignancies in various tissues remains an open
question. Here we report the interaction between CFTR and an adherens junction molecule, AF-6/afadin, and its
involvement in the development of colon cancer. We have found that CFTR and AF-6/afadin are co-localized at
the cell–cell contacts and physically interactwith each other in colon cancer cell lines. Knockdownof CFTR results
in reduced epithelial tightness and enhanced malignancies, with increased degradation and reduced stability of
AF-6/afadin protein. The enhanced invasive phenotype of CFTR-knockdown cells can be completely reversed by
either AF-6/afadin over-expression or ERK inhibitor, indicating the involvement of AF-6/MAPK pathway. More
interestingly, the expression levels of CFTR and AF-6/afadin are signiﬁcantly downregulated in human colon
cancer tissues and lower expression of CFTR and/or AF-6/afadin is correlatedwith poor prognosis of colon cancer
patients. The present study has revealed a previously unrecognized interaction between CFTR and AF-6/afadin
that is involved in the pathogenesis of colon cancer and indicated the potential of the two as novel markers of
metastasis and prognostic predictors for human colon cancer.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Colon cancer is among the top 5 main types of cancer and causes
608,000 deaths worldwide in 2008 according to WHO statistics. Al-
though the treatment of colon cancer has been improved in recent
years, it remains the second commonest cause of cancer deaths in the
United States [1]. The prognosis of patients with colon cancer varies
dramatically according to the metastatic status at diagnosis. Although
several prognostic scoring systems of metastatic colon cancer haveonductance Regulator; CF, cystic
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ights reserved.been developed for clinical practice [2–4], biomarkers that reliably
predict outcome of metastatic colon cancer are still lacking.
The correct establishment of apical–basal cell polarity is crucial for
normal epithelial barrier function. Loss of cell polarity not only results
in a leaky epithelium, but also plays a key role in the initialization of
tumorigenesis, epithelial–mesenchymal transition (EMT) and cancer
metastasis [5]. One of the multiple cellular processes that are required
for establishing cell polarity is the properly organized cell adhesion
and cell junction complexes. Cell–cell adhesion in epithelial cell sheets
is maintained mainly through adherens junctions (AJs) and tight
junctions (TJs). Several AJ components, e.g. E-cadherin and catenins,
have been a major focus of cancer studies since the expression and/or
integrity of AJ components are closely related to cancer progression
and metastasis [6,7]. AF-6, or afadin, is a novel intracellular AJ protein
interacting with the cytoplasmic region of nectins, which are
immunoglobulin-like cell adhesionmolecules at AJs, and linking nectins
to the actin cytoskeleton [8–11]. Interestingly, this set of adherensmol-
ecules has been implicated in the regulation of various cellular activities,
such as directional motility and proliferation, possibly through their
function in the organization of E-cadherin-based AJs and cell–cell
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recently found to be adversely correlated with the prognosis and
disease-free survival of breast cancer patients [12]. Subsequent func-
tional study revealed that loss of AF-6/afadin expression induced meta-
static phenotype in breast cancer cells via activation of ERK pathway
[13]. However, the involvement of other protein(s) interacting with
AF-6/afadin in cancer development has not been explored.
CFTR is a cAMP-activated chloride channel localized at the apical
membrane of epithelial cells in various tissues. Mutation of CFTR results
in cystic ﬁbrosis (CF), a common life-threatening autosomal recessive
disease, with a wide range of clinical manifestations such as digestive
tract obstruction, pulmonary inﬂammation and pancreatic insufﬁciency
[14,15]. Of note, along with the elongation of life span in CF patients
due to improved treatment strategies, new clinical complications are
emerging. Particularly, there has been a recent interest in the risk of
various cancers in CF patients and carriers of CFTR mutations [1,16–20].
Particularly, in a recent study involving 41,188 cases of CF patients
followed from 1990 to 2009 in the US,Maisonneuve et al. reported an el-
evated risk of digestive tract cancer including the esophago-gastric junc-
tion, biliary tract, small bowel, and colon [21]. More interestingly, the
CFTR gene itself has been reported to be frequently hypermethylated in
various cancer cell lines and tumor samples [22–25], indicating that dys-
function of CFTR might have a critical role in the pathogenesis of cancer.
The potential link between CFTR and epithelial cell polarity has been rec-
ognized since the identiﬁcation of CFTRmolecule. In several different cell
lines, including colon and pancreatic cancer cells, the anchorage of
functional CFTR to cell membrane was found to occur in step with the
polarization of these cells during culture [26–28]. In addition, CFTR was
required for the organization and integrity of tight junctions, which is a
necessity for the normal barrier function of epithelial cells [29]. Based
on the above association of CFTR and cancer risk, the link between
CFTR and cell polarity, and the importance of cell junction proteins in
the process of cancer progression and metastasis, we proposed that
CFTR may interact with cell junction proteins, AF-6/afadin in particular,
disruption of which may contribute to cancer development and
progression.
In the present study,we used both human colon cancer cell lines and
tissue specimens to investigate the potential interaction between CFTR
and AF-6/afadin, their functional roles in metastasis and their potential
as prognosis predictors of colon cancer.
2. Materials and methods
2.1. Antibodies and reagents
Anti-C-terminal-CFTR (CFTR-C) was purchased from Alomone Labs
(Jerusalem, Israel) and anti-N-terminal-CFTR (CFTR-N) was from
Santa Cruz Biotechnology. AF-6/afadin was obtained from Santa Cruz
Biotechnology (sc-14808 and sc-135823, Santa Cruz, CA, USA). Anti-
phospho-ERK and anti-ERK were obtained from Cell Signaling Technol-
ogy (Danvers, MA, USA). Anti-GAPDH was obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-Ras and anti-N-terminal-
CFTR were purchased from Millipore Company (Billerica, MA, USA).
U0126 was obtained from Sigma-Aldrich (St. Louis, MO, USA). Matrigel
was purchased from BD Biosciences (San Jose, CA, USA).
2.2. Cell culture and transfection
Human colon cancer cell lines HRT-18, RKO, SW480 and SW1116, as
well as HEK-293FT were obtained from ATCC, grown in DMEM/F12 or
RPMI-1640 medium supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin, and maintained in an atmosphere of 5%
CO2 and 95% O2 at 37 °C. All cell culture medium and antibiotics were
obtained from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum
was purchased from Life Technologies Ltd. (Grand Island, NY, USA).For stable transfection, HRT-18 cells were seeded in a 6-well plate at
0.5 × 106/well. After incubation for 12–24 h, cells were transfected
with 3 μg pcDNA6.2-miR-CFTR or pcDNA6.2-miR-lacz using 6 μl lipo-
fectamine 2000 (Life Technology Ltd., NY, USA). 24–72 h post transfec-
tion, cells were selected in full medium containing 15 μg/ml Blasticidin
for 4 weeks. Stable cell cloneswere then selected andmaintained in full
medium containing 5 μg/ml Blasticidin. For transient knockdown in
RKO cells, hammerhead ribozymeswere designed based on the second-
ary structure of CFTR using the Zuker RNA mFold program [30],
targeting at a speciﬁc GUC or AUC site as described before [31]. For
AF-6/afadin over-expression experiments, cells were transfected with
pcDNA3.1-Flag-AF6 or pcDNA3.1 using lipofectamine 2000 as men-
tioned above. Transfected cells were harvested for RNA and protein ex-
traction or seeded for cell invasion assay after 24–72 h. The pcDNA3.1
plasmid expressing AF-6/afadin was provided kindly by Professor
Marc Lopez (University of Mediterranee, Marseille, France). Mock con-
trol with no plasmids was included in this experiment.2.3. Cell adhesion assay
20,000 cells were seeded on 96-well plates pre-coatedwith 50 μg/ml
Matrigel and then blocked with 10 mg/ml BSA. After 4 h, the cells were
washed with PBS and ﬁxed with 5% glutaraldehyde for 20 min before
being stained with 0.1% Crystal Violet for 30 min. After washing and
air-dry, the crystal violet was dissolved in 10% (v/v) acetic acid and the
absorbance was read by spectrophotometer at 570 nm.2.4. Cell invasion assay
Invasion assay was carried out with 6.5 mm Transwell with 8 μm
Pore Polycarbonate Membrane Inserts (Corning Incorporated, MA,
USA) pre-coated with 500 μg/ml Matrigel. Cells were seeded to the
top of transwells at 20,000 cells/well. After incubation of 1–3 days
with 10 μM U0126 or DMSO, the inside of transwells was wiped 4
timeswith cotton tips to remove uninvaded cells. Cells that had invaded
through the membrane of transwells were ﬁxed in 4% paraformalde-
hyde for 15 min before being stained with 0.5% crystal violet solution.
The number of invaded cells was counted under a microscope. At least
6 random ﬁelds were counted for each transwell. The experiment was
repeated for three independent times.2.5. Wound-healing assay
Cells were seeded in 6-well plates at 2 × 106 cells/well and incubat-
ed overnight before creating a wound across the cell monolayer with a
plastic tip. The closure of the wound via the migration of cells into the
wound was tracked and recorded using a realtime live cell imaging mi-
croscope system (Carl Zeiss, Oberkochen, Germany) at 1 hour interval
for 24 h. Cell migration ability was determined by measuring reduced
areas of the wound. The experiment was repeated for three indepen-
dent times.2.6. Colony formation assay
Cells were mixed with 0.3% soft agar in DMEM/F12 medium supple-
mentedwith 10% FBS and 1% penicillin/streptomycin, and seeded on top
of a layer of 0.6% agar in 6-well plates at 3000 cells per well. After incu-
bation at 37 °C in 5% CO2 for 2 weeks, colonies were stained with 0.01%
crystal violet. Colony formation was evaluated by counting number of
colonies containing more than 20 cells under a microscope. At least 6
random ﬁelds were counted for each well. The experiment was repeat-
ed for three independent times.
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Cells were collected and washed once using PBS. RIPA buffer
(150 mM NaCl, 50 mM Tris–Cl, 1% NP-40, 0.5% DOC, 0.1% SDS, 1:100
PMSF, and 1:200 PImix) was used to lyse cells for 60 min at 4 °C. Super-
natant was collected as total protein after centrifugation at 12,000 rpm
for 30 min. Equal amounts of protein were separated by SDS-PAGE and
immunodetected for target proteins. The protein bands were visualized
by the enhanced chemiluminescence (ECL) assay (Amersham) follow-
ing manufacturer's instructions and scanned by densitometer. Experi-
ments were repeated for three times and the bands scanned and
quantiﬁed. Most of the experiments detecting AF-6/afadin used SC-
14808, except for detection of AF-6/afadin in RKO and HRT-18 cell
lines (sc-135823).
2.8. RNA extraction and RT-PCR
Total RNA of cells was extracted using TRIzol reagent (Invitrogen
Corporation, NY, USA) according to the manufacturer's instructions. 3–
5 μg total RNA was applied on reverse transcription reaction using
moloney murine leukemia virus reverse transcriptase (M-MLV). The
forward primer of AF-6/afadin is 5′-CTGACCATCCAGCTCTTCT-3′, and
the reverse primer of AF-6/afadin is 5′-CAAGTACCTGGTGAACGTG-3′.
PCR was carried out in triplicate on an Applied Biosystems PRISM PCR
system (Life Technologies Corporation, California, USA). The conditions
of PCR reaction were: 94 °C 4 min, 94 °C 30 s, 55 °C 30 s, 72 °C 30 s,
repeat 35 cycles, and 72 °C 10 min. The results were analyzed by
sequence detection system software v2.2.1 (Life Technologies Corpora-
tion, California, USA).
2.9. Real time quantitative PCR
The transcription expression levels of CFTR and AF-6/afadin in
human colon tissues were quantiﬁed by real time quantitative PCR,
based on the Ampliﬂuor technology as previously reported [32]. 3 μg
total RNA was applied to reverse transcription using M-MLV Reverse
Transcriptase (GE Healthcare, WI, USA). Speciﬁc TaqMan primer and
probes for human CFTR were purchased from Applied Biosystems.
Quantitative PCR reactions were carried out in triplicate on a 96-well
plate using an Applied Biosystems 7500 Fast Real-Time PCR System.
The transcriptional expression of CFTR was indicated with average Ct
normalized by Ct value of GAPDH.
2.10. Fluorescent immunocytochemistry
Cells were grown on glass coverslips or transwell coated with
Matrigel Basement Membrane Matrix (BD Biosciences, CA, USA). After
incubation for 3–10 days, cells on coverslips were ﬁxed in freshly
mixed acetone and methanol. Cells on transwells were then blocked
in 1% BSA bovine serum albumin (BSA) and incubated overnight in pri-
mary antibody at 4 °C. On the following day, secondary antibodies were
applied on cells for 1 h at room temperature. The nucleus was stained
with Hoechst 33342. Negative control group that omitted primary anti-
body was included in this study. The membrane of transwells was then
cut off and ﬁxed on coverslips, and visualized under confocal laser
scanning microscopy.
2.11. Immunohistochemistry
Frozen sections of colon cancer tissues and normal background tis-
sues were prepared by cryostat sectioning, air-dry and ﬁxation in mix-
ture of acetone and methanol. The sections were then incubated for
5–10 min in Optimax (Vector Laboratories Ltd., Peterborough, UK)
wash buffer to rehydrate, and in a 0.6% BSA blocking solution for
20 min. After incubation for 2 h in CFTR or AF-6/afadin primary anti-
body at room temperature and the following washings, the sectionswere incubated in secondary antibody for 30 min. Following extensive
washing, avidin biotin complex and diaminobenzidine chromogen
(Vector Laboratories Ltd.) were applied to the sections. At last, the sec-
tions were counterstained in hematoxylin, rehydrated in ascending
grades of methanol, cleared in xylene, and mounted under coverslips.
2.12. Co-immunoprecipitation assay
Cells were allowed to grow in 75 cm2 ﬂask till conﬂuency. Protein
interactions were ﬁxed using 200 μg/ml DTSSP (containing 0.1% Triton
X-100) for 20 min. The cross-link reaction was terminated by 50 mM
glycine for 5 min. Then cells were lysed with ice-cold lysis buffer
(50 mM HEPES, pH 8.3, 420 mM KCl, 0.1% NP-40, 1 mM EDTA) for
30 min on ice. Supernatant was collected after centrifugation at
14,000 rpm at 4 °C for 15 min. 100 μl supernatant was saved as input
and stored at−80 °C. The spin-down cells were incubated with 5 μg
anti-N-terminal-CFTR antibody or normalmouse IgG togetherwith Pro-
tein A/G (Santa Cruz, CA, USA) at 4 °C overnight with rotation. The
beads were harvested by centrifugation on the following day and
washed 5 times using PBS. Sample loading buffer was added to the
beads and incubated for 30 min at room temperature. The results
were analyzed by Western blotting.
2.13. Trans-epithelial resistance (TER)
TER was measured with the Millicell-ERS (Electrical Resistance Sys-
tem) (Millipore, CA, USA). Cells were seeded into the 0.4 mm pore size
transwell (upper chamber) and allowed to reach full conﬂuence. After
medium was replaced, electrodes were placed at the upper and lower
chambers and resistance was measured with the voltohmmeter.
2.14. Permeability assay
Epithelial permeability was determined using ﬂuorescently
labeled dextran FITC-Dextran-40, molecular weight being 10 kDa
(Sigma-Aldrich, MO, USA). Cells were prepared and treated as in
the TER study. After replacing medium, Dextran-40 was added to
the inside of transwells. Medium from the outside of transwells
was collected 20 min after the addition of FITC-dextran. The amount
of ﬂuorescence from these collections was read on a multichannel
ﬂuorescence reader (PerkinElmer, MA, USA).
2.15. Clinical samples and prognosis analysis
Colon cancer tissues and normal background tissues were collected
with ethical approval and informed consent from patients in University
Department of Surgery, Cardiff University School of Medicine, Cardiff,
UK. All tissues were collected immediately after surgery, snap frozen in
liquid nitrogen and stored at−70 °C. Patients were routinely followed
after surgery. The median follow-up period was 120 months. Details of
histologywere obtained frompathology reports and conﬁrmed by a con-
sultant pathologist. Statistical analysis was performed using the Minitab
(Minitab Ltd., Coventry, UK) statistical software package (version 14).
The two sample t-test was used for normally distributed data. Kaplan–
Meier survival analysis was performed using SPSS statistical software
(version 11; SPSS. Chicago, IL, USA). Patients were divided into high or
low levels of CFTR or AF6 based on the median level of the respective
molecule of colorectal tumors. The combined CFTR/AF6 analysis was
based on the deﬁnition that tumors with both CFTR and AF6 at high
levels were deﬁned as high level and tumor with either or both CFTR
and AF6 at low levels deﬁned as low level. Disease free survival was de-
ﬁned as the minimum interval from the date of diagnosis to the date of
tumor recurrence, progression, occurrence of a second malignancy,
death, or last follow-up. Overall survival was deﬁned as the interval
from the date of diagnosis to the date of death or last follow-up. Differ-
ences were considered to be statistically signiﬁcant at p b 0.05.
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[33]. 1 μg of total RNA was used to generate cDNA with a Reverse Tran-
scription (RT) kit (AbGene Laboratories, Essex, England, UK). ThemRNA
levels of CFTR andAF-6/afadinwere determined using a real-timequan-
titative PCR as described previously [33]. For immunohistochemistry
frozen tissues were sectioned using a cryostat and stored in−70 °C.a
c
b
CFTR AF-6/afadin
xy
xz
CFTR / DAPI
merge
Donkey anti mouse 568
DAPI
Fig. 1. CFTR co-localizes with AF-6/afadin in Caco-2. a) After polarized Caco-2 grew to conﬂuen
image of double-stained ﬂuorescent immunocytochemistry showing the co-localization of CFTR
bar = 10 μm. b)Negative control experiments showing the stainingwith secondary antibodies
staining in the cytoplasm. c) Confocal analysis on Caco-2monolayerswas performedwith CFTR
indicates the level of xz reslice (scale bar = 5 μm). Note the co-localization of CFTR and AF-6/a
was due to the non-speciﬁc staining in the cytoplasm, while CFTR had speciﬁc staining in the c2.16. Statistical analysis
Data were expressed as the mean ± SEM. Differences in measured
variables between two groups were assessed by using Student's t
tests. One way ANOVA was applied when there were more than two
groups. Results were considered statistically signiﬁcant at p b 0.05.merge
AF-6/ DAPI
Donkey anti rabbit 488
Donkey anti mouse 568
DAPI
Donkey anti rabbit 488
cy, the cell monolayer on basement membrane was processed to frozen section. Confocal
(CFTR-N, green) and AF-6/afadin (sc-14808,red) in the apical epithelial membrane. Scale
only (primary antibodies omitted). Note that anti-mouse Alexa 568 had some non-speciﬁc
-C and AF-6/afadin antibodies. xy, horizontal section; xz, vertical section. Arrow in xy panel
fadin at both apical membrane and cell–cell junctions. The diffused staining of AF-6/afadin
ytoplasm.
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3.1. CFTR co-localizes and physically interacts with AF-6/afadin in human
colon cancer cells
To investigate whether CFTR and AF-6/afadin interact with each
other, we ﬁrst checked whether CFTR and AF-6/afadin were co-
localized in polarized culture of human colon cancer cell line Caco-2. Re-
sults of confocal laser scanning microscopy showed that CFTR localized
not only at the apical membrane of cells, but also within the cytoplasm.
In contrast, AF-6/afadin localized only at the apical membrane and cell–
cell contact sites, but not in cytoplasm. CFTR (green, CFTR-N) and AF-6/
afadin (sc-14808, red) were overlapped at the apical membrane of
Caco-2 (Fig. 1a). In addition, confocal analysis on Caco-2 monolayer
also demonstrated the co-localization of CFTR and AF-6/afadin at the
cell–cell junctions in both xy and xz scanning planes of Caco-2
(Fig. 1c). The co-localization of CFTR and AF-6/afadin was validated
with another CFTR antibody targeting the C-terminus (CFTR-C, Supple-
mentary Fig. 1). Then we used co-immunoprecipitation (co-IP) to
further test if CFTR physically interacts with AF-6/afadin in the cellular
context. Plasmids expressing CFTR and AF-6/afadin were co-
transfected in 293FT cells. Cell lysates containing over-expressed pro-
teins were then immunoprecipitated with anti-CFTR or AF-6/afadin
antibodies together with protein A/G beads, and analyzed by Western
blotting. As shown in Fig. 2a, we found that both CFTR and AF-6/afadin
were detected in the immunoprecipitates of either anti-CFTR or anti-
AF-6/afadin antibody, but not in the immunoprecipitates of IgG control,a
b
input CFTR Ig
IP: CFTR
IB: anti-CFTR(C)
IB: anti-AF-6/afadin
293FT
c
BlkAF-6/
afadinWT 508 PDZ
AF-6/afadin+CFTR
CFTR(C)
CFTR(N)
AF-6/afadin
170kD
150kD
170kD
150kD
293FT
input CFTR Ig
IP: CFTR
IB: anti-CFTR(C)
IB: anti-AF-6/afadin
Caco-2
200kD
180kD
Fig. 2.Protein–protein interaction between CFTR andAF-6/afadin. a) Plasmids expressing CFTR a
G beads together with anti-CFTR antibody (CFTR-C), anti-AF-6/afadin antibody (sc-14808) or Ig
C) and anti-AF-6/afadin antibodies. b) Cell lysate of Caco-2 cells was incubated with protein A
body. The harvested beads were analyzed by Western blotting using anti-CFTR (CFTR-C)
interacting-motif CFTR and plasmids expressing AF-6/afadin were co-transfected respectively
(CFTR-C), anti-N-terminal-CFTR (CFTR-N) and anti-AF-6/afadin antibodies. (150 kD: immature
and AF-6). d) Cell lysate of 293FT cells that are co-transfected with AF-6/afadin and 3 differen
antibody. The harvested beads were analyzed byWestern blotting using anti-N-terminal-CFTRsuggesting that CFTR interactedwith AF-6/afadin in vitro. In addition, in
colon cancer cells, we found that CFTR and AF-6/Afadin interacted with
each other in vivo (Fig. 2b & Supplementary Fig. 2).
Given that CFTR contains a PDZ-interacting motif at its C-terminus,
which is responsible for its interaction with other PDZ domain-
containing proteins, we further investigated if the interaction of CFTR
and AF-6/afadin was dependent on its PDZ-interacting motif. We were
also intrigued to test whether ΔF508 mutation affected the binding of
CFTR and AF-6/afadin, since ΔF508 mutation is the most common CF-
associated mutation which generates immature protein resulting in de-
fective trafﬁcking of the protein to cell membrane [34]. Plasmids ex-
pressing wild-type CFTR (WT) and two mutations of CFTR (ΔF508 or
ΔPDZ-interacting-motif) were co-transfected with AF-6/afadin into
293FT cells and the overexpression was conﬁrmed by using two differ-
ent CFTR antibodies targeting either C terminus (CFTR-C) or N-terminus
(CFTR-N). As shown in Fig. 2c, ectopic expression ofWT andΔF508CFTR
could be detected by both CFTR-C and CFTR-N antibodies. In WT
transfectants, both glycosylated (mature) protein at 170 kD and imma-
ture protein at 150 kDa can be detected. However, in ΔF508
transfectants, only immature protein was overexpressed. Interestingly,
we found that the interaction between CFTR and AF-6/afadin could
only be detected in wild-type CFTR transfected cells. Neither ΔF508
nor ΔPDZ-interacting-motif mutated CFTR physically interacted with
AF-6/afadin (Fig. 2d). Taken together, these results suggest that the
physical interaction between CFTR and AF-6/afadin is via PDZ
interacting motif. Moreover, normal trafﬁcking of CFTR to cell mem-
brane is required for the interaction between CFTR and AF-6/afadin,G input AF-6/
afadin IgG
IP: AF-6/afadin
170kD
150kD
d
AF-6/
afadinWT 508 PDZ
AF-6/afadin+CFTR
IB:CFTR(N)
IB:AF-6/
afadin
170kD
150kD
IP with AF-6/afadin
293FT
G input AF-6/
afadin
IgG
IP: AF-6/afadin
170kD
150kD
200kD
180kD
200kD
180kD
200kD
180kD
ndAF-6/afadinwere cotransfected in 293FT cells. Cell lysatewas incubatedwith proteinA/
G control. The harvested beadswere analyzed byWestern blotting using anti-CFTR (CFTR-
/G beads together with anti-CFTR (CFTR-C), anti-AF-6/afadin antibody or IgG control anti-
and anti-AF-6/afadin antibodies. c) Plasmids expressing wild type, ΔF508 or ΔPDZ-
in 293FT cells. Cell lysate was analyzed by Western blotting using anti-C-terminal-CFTR
CFTR; 170 kD: mature CFTR. “Blk” indicates naïve HEK-293 without transfection of CFTR
t designs of CFTR were incubated with protein A/G beads together with anti-AF-6/afadin
.
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with AF-6/afadin. Taken together, these data suggest that CFTR and
AF-6/afadin may form or be part of a protein complex in colon cancer
cells.3.2. CFTR is critical for the maintenance of colon epithelial tight junctions
To investigate the possible functions of CFTR/AF6 protein complex,
weﬁrst determined the role of CFTR in themaintenance of colon epithe-
lial tightness. Human colon cancer cell, HRT-18, was transfected with
pcDNA6.2-miR-CFTR plasmid to knockdown CFTR expression. A sub-
stantial reduction of CFTR expression was observed at both mRNA
(Fig. 3a) and protein (Fig. 3b) levels. We then examined whether sup-
pression of CFTR affected epithelial tightness using transepithelial
resistance (TER) and epithelial permeability assays in cells reaching
conﬂuence. Our results showed that the TER of miR-CFTR cells was
markedly reduced compared to miR-lacZ cells at the 4th and 7th daya
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CFTR cells (Fig. 3e), suggesting that CFTR knockdown decreases the ex-
pression of AF-6/afadin at post-translational level, probably by increas-
ing its protein degradation. Given that AF-6/afadin has been reported to
degrade via proteasome pathway [35], we used a proteasome inhibitor
(MG132) to check if the reduction of AF-6/afadin in miR-CFTR cells
could be rescued by MG132. Our result showed that in the presence of
MG132, the decreased expression of AF-6/afadin in miR-CFTR cells
was partially reversed compared to miR-lacZ cells (Fig. 3f). We then
used a protein synthesis inhibitor, cycloheximide (CHX) to block the
de novo synthesis of AF-6/afadin and further conﬁrmed if CFTR knock-
down increased the protein degradation of AF-6/afadin. Our results
showed that the protein degradation of AF-6/afadin in miR-CFTR cells
was signiﬁcantly faster than that in miR-lacZ cells (Fig. 3g). These data
reveal that suppression of CFTR expression results in increased protein
degradation of AF-6/afadin. Since CFTR physically interacts with AF-6/
afadin, it is plausible that CFTR stabilizes AF-6/afadin and prevents
its degradation in colon epithelial cells. In addition to protein stability,
we also checked if the localization of AF-6/afadin was affected by
CFTR knockdown. Immunoﬂuorescence staining showed that although
AF-6/afadin localized at cell–cell contacts in a verywell-organizedman-
ner in control cells, CFTR knockdown resulted in a disorganized expres-
sion pattern of AF-6/afadin withmost of the staining translocated to the
cytoplasm (Supplementary Fig. 3). Collectively, these data suggest that
CFTR is required for the epithelial barrier function of human colon
epithelial cells, loss of which impairs epithelial tightness probably via
reduction or disturbed intracellular organization of AF-6/afadin.
3.4. Suppression of CFTR aggravates the malignant phenotypes of colon
cancer cells through activation of ERK pathway
Since loss of epithelial tightness is considered as one of the
characteristics ofmalignant cancers, we then investigatedwhether sup-
pression of CFTR could affect the malignant phenotypes of colon cancer
cells.While there was no signiﬁcant difference in anchorage-dependent
cell growth between miR-CFTR and miR-lacZ cells (Supplementary
Fig. 5a), the frequencies of colony formation inmiR-CFTR cells were sig-
niﬁcantly higher than those in miR-lacZ cells (Fig. 4a). In addition, our
results also demonstrated that suppression of CFTR signiﬁcantly en-
hanced cell migration and invasion in HRT-18 cells (Fig. 4b & c). Similar
results were found in another CFTR-knockdown human colorectal can-
cer cell line RKO (Supplementary Fig. 5b–f). Taken together, these data
indicate that suppression of CFTR expression results in the aggravated
malignancy of colon cancer cells.
It has been recently reported that loss of AF-6/afadin increases mi-
gration and invasion of breast cancer cells via activation of ERK signaling
pathway [13]. Activation of ERK is known to trigger a number of down-
stream pathways, such as NF-κB, uPA and MMPs, that facilitate cell mi-
gration and invasion [36,37]. We thus hypothesized that suppression of
CFTR expression in colon cancer cells decreases protein stability and
levels of AF-6/afadin, leading to activation of ERK and augmentation of
cell malignancy. To test this hypothesis, we ﬁrst analyzed total and
phosphorylated ERK in control and CFTR knockdown HRT-18 cells by
Western blotting. The results showed that phosphorylated ERK was
up-regulated in miR-CFTR cells, while total ERK was not affected
(Fig. 4d). Next, we reasoned that if the enhanced activation of ERK
was due to the loss of AF-6/afadin, the effects observed with CFTR
knockdown should be reversed by recovery of AF-6/afadin. To test
this, we over-expressed AF-6/afadin in miR-CFTR and miR-lacZ cells
and evaluated their changes in ERK phosphorylation and invasive phe-
notypes. Our results showed that the increased phosphorylation of
ERK was signiﬁcantly reversed by AF-6/afadin over-expression in miR-
CFTR cells (Fig. 4e). More strikingly, over-expression of AF-6/afadin
completely abolished the increased cell invasion in miR-CFTR cells
(Fig. 4f). Then we further tested whether enhanced cell invasion in
CFTR knockdown cells could be attributed to ERK activation by using aspeciﬁc ERK inhibitor, U0126. As assessed by invasion assay, treatment
of U0126 completely abrogated the increased cell invasion of miR-
CFTR cells but not that of miR-lacZ cells (Fig. 4g). Meanwhile, ourWest-
ern blot results showed that U0126 treatment completely reversed the
activation of ERK in both miR-lacZ and miR-CFTR HRT-18 cells
(Fig. 4h). In contrast, U0126 treatment could not reverse the upregula-
tion of Ras expression in CFTR knockdown cells, indicating the speciﬁc-
ity of U0126 treatment. Taken together, these data suggest that the
effects of CFTR on malignancies of colon cancer cells are mediated by
AF-6/afadin through activation of ERK.
3.5. Lower expression of CFTR and AF-6/afadin is correlatedwith poor prog-
nosis of colon cancer patients
Having established that suppression of the interaction between CFTR
and AF-6/afadin promotes colon cancer cell progression, we set out to
examine the expressions of CFTR and AF-6/afadin in primary tumors
from colon cancer patients. In all normal tissues, immunohistochemistry
showed strong staining signals of CFTR speciﬁcally localized in the lumi-
nal side of crypts of Lieber-kühn. It is of interest that apart from apical
membrane, a signiﬁcant fraction of CFTR signals was localized at the in-
tercellular junction sites. In contrast, CFTR protein was almost complete-
ly lost in all the tumor tissues derived from three individuals with colon
cancer (Fig. 5a, upper panel). Similar to CFTR expression, results of im-
munohistochemistry from the consecutive sections of the same colon
cancer tissues also revealed that the expression of AF-6/afadin was al-
most undetectable in cancer tissue whereas localized speciﬁcally in the
apical membrane and cell–cell contact sites of epithelial cells in normal
tissues (Fig. 5a, lower panel). In one of the sections containing both
tumor tissue and adjacent normal tissue, we observed a transitional ex-
pression of AF-6/afadin with strong expression in the normal tissue but
absence of expression in tumor region (Supplementary Fig. 6).
To further assess the relative expression levels of CFTR and AF-6/
afadin in colon cancer, we performed a wider screening analyzing 94
colon cancer tissue samples and 75 normal tissues using real-time
PCR. Consistent with the expression pattern of protein, our results
showed that the level of CFTR mRNA in colon cancer tissues
(0.01392 ± 0.00490, n = 94) was dramatically lower than that in the
normal tissues (4.02 ± 3.90, n = 75) (Fig. 5b). We also examined the
correlation between the transcription expression levels of CFTR and
AF-6/afadin. As assessed by the Pearson's correlation analysis, the coef-
ﬁcient of CFTR and AF-6/afadin was 0.888 (n = 94, p b 0.0001)
(Fig. 5c), indicating that the expressions of CFTR and AF-6/afadin in
human colon cancer are highly positively correlated.
Next, we attempted to evaluate the prognostic potential of CFTR and
AF-6/afadin in colon cancer patients. We ﬁrst examined CFTR mRNA
levels in accordance with patients' TNM classiﬁcation. Statistical analy-
sis revealed that CFTR expression in patients with TNM4 stage
(0.000261 ± 0.000261, n = 6) was signiﬁcantly lower (p b 0.05)
than that in patients with TNM2/3 stage (0.0141 ± 0.0066, n = 56)
(Fig. 5d). Further analysis of CFTR mRNA levels according to patients'
metastasis status showed that CFTR expression in patients with metas-
tasis (0.000261 ± 0.000261, n = 6) was signiﬁcantly lower (p b 0.05)
than that in patients without metastasis (0.0136 ± 0.0063, n = 65)
(Fig. 5e). Since metastasis is the main cause of tumor relapse and high
mortality of human colon cancer, we also evaluated the prognostic po-
tential of CFTR and AF-6/afadin using clinical outcomes collected by a
follow-up study with the median of 120 months. Statistical analysis
showed that patients with low transcription expression of AF-6/afadin
had signiﬁcantly shorter overall survival than patients with high AF-6/
afadin expression (p = 0.033) (Fig. 6a). In addition, patients with low
expression of either or both CFTR and AF-6/afadin had a signiﬁcantly
shorter overall survival (p = 0.039) (Fig. 6b). These analyses indicate
that reduced expressions of CFTR and AF-6/afadin are signiﬁcantly
associated with cancer progression and poor prognosis of human
colon cancer patients.
(hours)
a c
miR-lacZ miR-CFTR
0
5
10
15
20 **
N
o.
 o
f c
ol
on
ie
s 
(/f
iel
d)
b
24 hrs 48 hrs 72 hrs
d e
lac
Z-c
trl
lac
Z-A
F6
ov
er
CF
TR
kd
-ct
rl
CF
TR
kd
-AF
6o
ve
r0.0
0.5
1.0
1.5
*** **
R
el
at
iv
e 
p-
ER
k 
pr
ot
ei
n
le
ve
l (/
ER
k)
AF6/
afadin
CFTR
P-ERK
ERK
GAPDH
miR-lacz miR-CFTR
CFTR
P-ERK
ERK
GAPDH
170kD
150kD
170kD
150kD
200kD
180kD
42kD
44kD
42kD
44kD
37kD
42kD
44kD
42kD
44kD
37kD
f g h
lac
Z-c
trl
lac
Z-A
F6
ov
er
CF
TR
kd
-ct
rl
CF
TR
kd
-AF
6o
ve
r0
25
50
75
*** **
N
o.
 o
f i
nv
as
iv
e 
ce
lls
 (/f
iel
d)
lac
Z-D
MS
O
CF
TR
kd
-DM
SO
lac
Z-U
01
26
CF
TR
kd
-U0
12
6
0
10
20
30
40
*** ***
N
o.
 o
f i
nv
as
iv
e 
ce
lls
 (/f
iel
d)
CFTR
P-ERK
ERK
Ras
GAPDH
U0126 - +- +
42kD
44kD
42kD
44kD
21kD
170kD
150kD
37kD
0 6 12 18 24 30
0
50
100
150
miR-lacZ
miR-CFTR
*
*
*
*
(hours)
0 hr 24 hrs
0 24 48 72
0
10
20
30
40
miR-lacZ
miR-CFTR
**
N
o.
 o
f i
nv
as
iv
e 
ce
lls
 (/f
iel
d)
m
iR
-la
cZ
 
m
iR
-C
FT
R 
M
ig
ra
te
d 
ar
ea
 /f
ie
ld
 (m
m2
)
m
iR
-la
cZ
m
iR
-C
FT
R
Ve
cto
r
AF
-6/
afa
din
AF
-6/
afa
din
Ve
cto
r
Fig. 4. Suppression of CFTR aggravates the malignant phenotypes of colon cancer cells through activation of ERK pathway. a) CFTR knockdown increased formation of colonies of HRT-18
cells as detected by soft agar assay (**p b 0.01, n = 3). b) Knockdown of CFTR promoted migration of HRT-18 cells in wound-healing assay (*p b 0.05, n = 3). Both control and CFTR
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Improved life expectancy among patients with CF has unmasked a
signiﬁcant increase in the incidence of gastrointestinal malignancies
[17,38–40]. Since the higher prevalence of cancer appeared to beassociated with CFTR-expressing sites, including epithelial surfaces of
the colorectal and the pancreatic and biliary ductal system, it was spec-
ulated that loss of CFTR function contributes to the pathogenesis of
gastrointestinal cancer. However, the exact role of CFTR in the develop-
ment of GI cancer remains elusive. In the present study, we have
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dent cell growth, cell migration and cell invasion in colorectal cancer
cells (Fig. 4a–c & Supplementary Fig. 5), indicating that CFTR is more in-
volved in the regulation of cancer progression and metastasis. Indeed,
using colon cancer cell lines that can undergo epithelial mesenchymal
transition (EMT), such as SW480 and SW1116, we have shown that
suppression of CFTR channel function by its speciﬁc inhibitor, inh172,
induces EMT as demonstrated by downregulation of epithelial markers
and upregulation of mesenchymalmarkers (Supplementary Fig. 7). One
of the characteristics of metastatic cancer cells is the loss of epithelial
polarity and cell–cell adhesions. In this study, we have demonstrated
that inhibition of CFTR impairs the formation of cell–cell junction as
manifested by a reduced TER and an increased permeability in CFTR
knockdown cells (Fig. 3c–d), indicating impaired cell–cell contact and
disrupted epithelial tightness. These observations suggest that function-
al CFTR is critical for themaintenance of the epithelial polarity and tight-
ness in colorectal epithelial cells, dysfunction of whichmay facilitate the
loss of their epithelial cell characteristics during cancer development,
becoming migratory and invasive, necessary for the metastasis process.
The notion that CFTR regulates cell–cell contact and thus cancerme-
tastasis is further supported by the ﬁnding that CFTR is closely associat-
ed with AF-6/afadin, a novel AJ molecule critical for AJ complex
formation and junctional architecture [41,42]. In the colorectal cancer
cells, CFTR and AF-6/afadin co-localize at the apical membrane and AJs
(Fig. 1a–c). The direct evidence of protein–protein interaction between
CFTR and AF-6/afadin comes from the co-IP experiment showing that
the two proteins physically interact with each other both in vitro and
in vivo in colorectal cancer cells (Fig. 2 and Supplementary Fig. 4). Inter-
estingly, an increasing number of proteins have been suggested to inter-
act directly or indirectly with CFTR to form macromolecular complexes
through its PDZ-binding motif [1], indicating that CFTR might play a
more complex and extensive role than we previously thought. For
instance,microscopic studies onHT-29monolayers have revealed prox-
imity but not co-localization of CFTR with ZO-1 [43]. Another proteo-
mics analysis of global CFTR protein interactions showed that E-
cadherin was among the numerous putative proteins interacting with
CFTR [44]. More signiﬁcantly, it has been noted that CFTR is required
for the normal organization and function of tight junctions, and that
loss of CFTR leads to abnormally low TER and loss of epithelial polarity
and integrity [29]. The present study has demonstrated for the ﬁrst
time that the interaction of CFTRwith AF-6/afadin,which is PDZdomain
dependent, as indicated by mutation of PDZ-binding motif in CFTR C-
terminal completely abolishes its interaction with AF-6/afadin. In addi-
tion, we have also demonstrated that normal trafﬁcking of CFTR to the
plasma membrane is critical for the interaction, since AF-6/afadin does
not interact with ΔF508 mutation, which is not able to trafﬁc to plasma
membrane due to proteinmisfolding (Fig. 2d). It appears that the struc-
tural integrity and apical expression of CFTR are critical for its interac-
tion with the junctional complex protein AF-6/afadin, and thus, the
maintenance of epithelial polarity since downregulation of CFTR results
in increased AF-6/afadin degradation and cellular dislocation (Fig. 3f, g
& Supplementary Fig. 3).
How is AF-6/afadin involved in CFTR-regulated cancer progression?
Although the role of AF-6/afadin in intestinal development is still ob-
scure, the loss of AF-6/afadin has been shown to cause increased
paracellular permeability and enhanced susceptibility to tissue destruc-
tion in the intestinal mucosa of conditional AF-6/afadin knockout mice
[45]. Thus, it is plausible that the disorganization of AF-6/afadin ac-
counts for the enhanced cell invasiveness in CFTR knockdown cells. In-
deed, enhanced cell invasion in CFTR knockdown cells was completely
reversed by overexpression of AF-6/afadin (Fig. 4f), indicating that the
tumor suppressive effects of CFTR on colorectal cancer progression are
mostly, if not all, attributed to AF-6/afadin. It has been reported that
AF-6/afadin interacts with Ras and is a putative effector of Ras leading
to MAPK activation [46]. Meanwhile, activation of Ras/MAPK pathway
is found to promote cancer metastasis and invasion in various types oftissues [13,47,48] through multiple downstream targets, such as NFκB
and uPA. In our experiments, we have shown that CFTR knockdown ac-
tivates ERK, which can be reversed by AF-6/afadin overexpression
(Fig. 4e). In addition, we have shown that CFTR knockdown-enhanced
cell invasion is virtually reversed by p44/42 MAPK inhibitor, U0126
(Fig. 4g), indicating that the role of CFTR in cancer invasion is attributed
to the AF-6/afadin/MAPK pathway. Apart from ERK, we also found that
knockdown of CFTR in HRT-18 cells up-regulates several downstream
targets of ERK, such as NFκBp65 and uPA (Supplementary Fig. 8). Of
note, in our previous study, we have demonstrated that CFTR sup-
presses prostate cancer progression through miR-193b-medicated
regulation of uPA [31]. While protein–protein interaction was not ex-
amined in that study, these ﬁndings indicate that CFTR may regulate a
metastatic process through distinct tissue-speciﬁc pathways in different
types of cancer.
Although treatments of colon cancer have been improved in recent
years, it remains the second commonest cause of cancer deaths in the
United States [1]. This is partly because of our incomplete understand-
ing of the biochemical mechanisms underlying the acquisition of the in-
vasive phenotype and the lack of reliable biomarkers that predict the
outcome of metastatic disease. In the present study, we have revealed
that reduced expression of CFTR is associated with the TNM staging
and poorer prognosis of colon cancer (Fig. 5). Moreover, in consistent
with the previous report in breast cancer [12], we have found that AF-
6/afadin expression is also inversely associated with survival in colon
cancer patients (Fig. 6a). These results, along with other studies show-
ing abnormal CFTR expression in various cancers due to mutation or
hypermethylation [22–24], warrant future investigations into the po-
tential of using both CFTR and AF-6/afadin as prognostic indicators,
which are likely to provide attractive and novel targets for prognosis
and therapeutic intervention of colorectal cancer.
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